Stocks · Korea
003000
KOSPI
Bukwang Pharmaceutical IND
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-07 basis
PER28.09x
PBR1.24x
EPS152 KRW
BPS3,452 KRW
ROE4.11%
Dividend yield2.93%
DPS125 KRW
Payout ratio82.24%
Returns and 52-week range
1W+7.15%
1M+5.69%
3M+2.64%
6M-44.62%
1Y+14.32%
YTD+11.49%
52W high9,890원
52W low3,460원
From 52W high-56.83%
Financial results (consolidated)
| Period | Revenue | Operating income | Net income | OP margin |
|---|---|---|---|---|
| 2022 | 1,909억 | -2억 | -42억 | -0.1% |
| 2023 | 1,259억 | -375억 | -344억 | -29.8% |
| 2024 | 1,601억 | 16억 | -35억 | 1.0% |
| 2025 | 2,007억 | 142억 | 124억 | 7.1% |
| Quarterly | ||||
| 2024 4Q | 462억 | 20억 | 18억 | 4.2% |
| 2025 1Q | 478억 | 30억 | -1억 | 6.3% |
| 2025 2Q | 426억 | 20억 | 64억 | 4.7% |
| 2025 3Q | 478억 | 10억 | 15억 | 2.0% |
| 2025 4Q | 625억 | 82억 | 47억 | 13.1% |
| 2026 1Q | 478억 | 11억 | 12억 | 2.3% |
Company
Address: 서울특별시 동작구 대방동1길 47
Peers in the same sector
Recent filings
- 2026-08-13반기보고서 (2026.06)
- 2026-05-14분기보고서 (2026.03)
- 2026-03-16사업보고서 (2025.12)
- 2025-11-14분기보고서 (2025.09)
- 2025-08-14반기보고서 (2025.06)
- 2025-07-04[기재정정]주요사항보고서(유상증자결정) Major
- 2025-05-29[기재정정]주요사항보고서(유상증자결정) Major
- 2025-05-08분기보고서 (2025.03)
Source: DART (Financial Supervisory Service electronic disclosure)
Recent news
- 2026-06-08유니온제약 품은 부광약품…이사진 교체 추진 블로터
- 2026-06-04부광약품, ‘루라시돈’ 우울장애 치료 적응증 추가 IND 승인 디지털타임스
- 2026-06-04부광약품, ‘라투다’ 우울증 적응증 확대 임상 시작…우울증 시장 공.... 서울경제
- 2026-06-04부광약품, '라투다' 우울장애 적응증 추가 임상 돌입 머니투데이
- 2026-06-04부광약품 "라투다, 우울장애 적응증 추가 임상승인" 뉴시스
- 2026-06-03부광약품, '루라시돈' 우울장애 치료 적응증 추가 IND 승인 뉴스1
- 2026-06-03부광약품 ‘라투다’, 우울장애 적응증 확대 3상 승인…시장 영토 넓.... 헤럴드경제
- 2026-05-27부광약품, '빚 청소' 끝난 유니온제약 품는다 데일리안
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.